2 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
Follow EGFR Exon 19 Deletion: new trials by email Literature Review of EGFR Exon 19 Deletion trials Research Report on EGFR Exon 19 Deletion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC BLU-701, osimertinib, carboplatin - Lung Neoplasm, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 20 | 2022-01-13 | 2023-06-18 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC BLU-945, osimertinib - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 177 | 2021-06-29 | 2025-02-10 |
Adenocarcinoma (2) · Bronchial Neoplasms (2) · Carcinoma (2) · Carcinoma, Bronchogenic (2) · Carcinoma, Non-Small-Cell Lung (2) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Nerve Tissue (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2)
Bronchial Diseases (2) · Neoplasms, Glandular and Epithelial (2)
osimertinib (2) · Carboplatin (1) · Pemetrexed (1)
Blueprint Medicines Corporation (2)
United States (2) · Canada (1) · France (1) · Japan (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)